{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:11:48Z","timestamp":1788923508699,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.leukres.2023.107365","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T12:38:03Z","timestamp":1690461483000},"page":"107365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Management of humoral secondary immunodeficiency in hematological malignancies and following hematopoietic stem cell transplantation: Regional perspectives"],"prefix":"10.1016","volume":"133","author":[{"given":"Muhlis Cem","family":"Ar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"El Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saule","family":"Gabbassova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Alhuraiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Alsaeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilgun","family":"Sayinalp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7368-3998","authenticated-orcid":false,"given":"Mahmoud","family":"Marashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.leukres.2023.107365_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hon.2323","article-title":"Secondary immunodeficiency in lymphoproliferative malignancies","volume":"34","author":"Friman","year":"2016","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.leukres.2023.107365_bib2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/1744666X.2020.1807328","article-title":"A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants","volume":"16","author":"Monle\u00f3n Bonet","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"33","key":"10.1016\/j.leukres.2023.107365_bib3","first-page":"1","article-title":"The expanding field of secondary antibody deficiency: causes, diagnosis, and management","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.leukres.2023.107365_bib4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/cei.12915","article-title":"When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach","volume":"188","author":"Jolles","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.leukres.2023.107365_bib5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.leukres.2023.107365_bib6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/ejh.13580","article-title":"Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus","volume":"106","author":"Jolles","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2023.107365_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2016.00317","article-title":"Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy","volume":"7","author":"S\u00e1nchez-Ram\u00f3n","year":"2016","journal-title":"Front Immunol."},{"key":"10.1016\/j.leukres.2023.107365_bib8","doi-asserted-by":"crossref","unstructured":"Fitzmaurice C., Akinyemiju T.F., Al Lami F.H., Alam T., Alizadeh-Navaei R., Allen C., Alsharif U., Alvis-Guzman N., Amini E., Anderson B.O., Aremu O., Artaman A., Asgedom S.W., Assadi R., Atey T.M.H., Avila-Burgos L., Awasthi A., Saleem H.O., Barac A., Bennett J.R., Bensenor I.M., Bhakta N., Brenner H., Cahuana-Hurtado L., Casta\u00f1eda-Orjuela C.A., Catal\u00e1-L\u00f3pez F., Choi J.Y.J., Christopher D.J., Chung S.C., Curado M.P., Dandona L., Dandona R., Das Neves J., Dey S., Dharmaratne S.D., Doku D.T., Driscoll T.R., Dubey M., Ebrahimi H., Edessa D., El-Khatib Z., Endries A.Y., Fischer F., Force L.M., Foreman K.J., Gebrehiwot S.W., Gopalani S.V., Grosso G., Gupta R., Gyawali B., Hamadeh R.R., Hamidi S., Harvey J., Hassen H.Y., Hay R.J., Hay S.I., Heibati B., Hiluf M.K., Horita N., Hosgood H.D., Ilesanmi O.S., Innos K., Islami F., Jakovljevic M.B., Johnson S.C., Jonas J.B., Kasaeian A., Kassa T.D., Khader Y.S., Khan E.A., Khan G., Khang Y.H., Khosravi M.H., Khubchandani J., Kopec J.A., Kumar G.A., Kutz M., Lad D.P., Lafranconi A., Lan Q., Legesse Y., Leigh J., Linn S., Lunevicius R., Majeed A., Malekzadeh R., Malta D.C., Mantovani L.G., McMahon B.J., Meier T., Melaku Y.A., Melku M., Memiah P., Mendoza W., Meretoja T.J., Mezgebe H.B., Miller T.R., Mohammed S., et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016 a systematic analysis for the global burden of disease study global burden of disease cancer collaboration. JAMA Oncol. 2018;4:1553\u20131568.","DOI":"10.1001\/jamaoncol.2018.2706"},{"key":"10.1016\/j.leukres.2023.107365_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2014.00626","article-title":"Immunoglobulin replacement therapy in secondary hypogammaglobulinemia","volume":"5","author":"Compagno","year":"2014","journal-title":"Front Immunol."},{"key":"10.1016\/j.leukres.2023.107365_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/cei.12493","article-title":"Immunoglobulin G treatment of secondary immunodeficiencies in the era of novel therapies","volume":"178","author":"Sepp\u00e4nen","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.leukres.2023.107365_bib11","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.7150\/jca.29993","article-title":"Multiple myeloma: What do we do about immunodeficiency?","volume":"10","author":"Li","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.leukres.2023.107365_bib12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/ACI.0000000000000215","article-title":"Secondary antibody deficiencies","volume":"15","author":"Dhalla","year":"2015","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.leukres.2023.107365_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.tmrv.2016.06.006","article-title":"Subcutaneous immunoglobulin therapy for hypogammaglobulinemia secondary to malignancy or related drug therapy","volume":"31","author":"Windegger","year":"2017","journal-title":"Transfus. Med Rev."},{"key":"10.1016\/j.leukres.2023.107365_bib14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.7861\/clinmedicine.16-6-571","article-title":"Secondary antibody deficiency \u2013 causes and approach to diagnosis","volume":"16","author":"Srivastava","year":"2016","journal-title":"Clin. Med"},{"key":"10.1016\/j.leukres.2023.107365_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev."},{"key":"10.1016\/j.leukres.2023.107365_bib16","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2009.25.6693","article-title":"Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation","volume":"28","author":"Martin","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2023.107365_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5144\/1658-3876.2012.1","article-title":"Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation","volume":"5","author":"Majhail","year":"2012","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"10.1016\/j.leukres.2023.107365_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2016.00507","article-title":"Immune reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Ogonek","year":"2016","journal-title":"Front Immunol."},{"key":"10.1016\/j.leukres.2023.107365_bib19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/sj.bmt.1705892","article-title":"Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival","volume":"41","author":"Norlin","year":"2008","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.leukres.2023.107365_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/PAP.0000000000000032","article-title":"Hematopoietic stem cell transplantation: graft versus host disease and pathology of gastrointestinal tract, liver, and lung","volume":"21","author":"Kambham","year":"2014","journal-title":"Adv. Anat. Pathol."},{"key":"10.1016\/j.leukres.2023.107365_bib21","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/bmt.2014.28","article-title":"Risk factors for hypogammaglobulinemia after allo-SCT","volume":"49","author":"Arai","year":"2014","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.leukres.2023.107365_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/bmb\/ldn034","article-title":"The immunodeficiency of chronic lymphocytic leukaemia","volume":"87","author":"Hamblin","year":"2008","journal-title":"Br. Med Bull."},{"key":"10.1016\/j.leukres.2023.107365_bib23","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1182\/blood-2019-125232","article-title":"One and half million hematopoietic stem cell transplants (HSCT). Dissemination, trends and potential to improve activity by telemedicine from the worldwide network for blood and marrow transplantation (WBMT)","volume":"134","author":"Niederwieser","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107365_bib24","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.leukres.2023.107365_bib25","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.bbmt.2016.04.005","article-title":"Immune-mediated complications after hematopoietic stem cell transplantation","volume":"22","author":"Li","year":"2016","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.leukres.2023.107365_bib26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clim.2017.11.014","article-title":"Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial","volume":"191","author":"Vacca","year":"2018","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.leukres.2023.107365_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/ejh.12900","article-title":"Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: long-term data of the SIGNS study","volume":"99","author":"Reiser","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2023.107365_bib28","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1002\/eji.201444700","article-title":"European consensus proposal for immunoglobulin therapies","volume":"44","author":"Sewell","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.leukres.2023.107365_bib29","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/1744666X.2016.1208085","article-title":"Prophylactic immunoglobulin therapy in secondary immune deficiency \u2013 an expert opinion","volume":"12","author":"Agostini","year":"2016","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"58","key":"10.1016\/j.leukres.2023.107365_bib30","first-page":"e44","article-title":"IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"2014","author":"Rubin","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.leukres.2023.107365_bib31","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European myeloma network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2023.107365_bib32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10875-007-9088-9","article-title":"Intravenous immunoglobulin: an update on the clinical use and mechanisms of action","volume":"27","author":"Negi","year":"2007","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.leukres.2023.107365_bib33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.transci.2016.12.017","article-title":"Mechanisms of action of intravenous immunoglobulin","volume":"56","author":"Chaigne","year":"2017","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.leukres.2023.107365_bib34","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/ejh.13223","article-title":"Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies","volume":"102","author":"Na","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.leukres.2023.107365_bib35","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.21873\/anticanres.12712","article-title":"Efficacy-safety of facilitated subcutaneous immunoglobulin in immunodeficiency due to hematological malignancies. A single-center retrospective analysis","volume":"38","author":"Dimou","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.leukres.2023.107365_bib36","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2217\/imt.14.34","article-title":"Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies","volume":"6","author":"Wasserman","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1016\/j.leukres.2023.107365_bib37","doi-asserted-by":"crossref","unstructured":"Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med. 1988;319:902\u2013907.","DOI":"10.1056\/NEJM198810063191403"},{"key":"10.1016\/j.leukres.2023.107365_bib38","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau\u2010phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2023.107365_bib39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.1994.tb05002.x","article-title":"Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes","volume":"88","author":"Chapel","year":"1994","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2023.107365_bib40","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jaci.2012.06.021","article-title":"Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency","volume":"130","author":"Wasserman","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.leukres.2023.107365_bib41","first-page":"1","author":"Borte","year":"2023","journal-title":"Facil. Subcutaneous Immunoglobulin Treat. Patients Immunodefic.: FIGARO Study J. Clin. Immunol. Publ. Online"},{"key":"10.1016\/j.leukres.2023.107365_bib42","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10238-020-00633-4","article-title":"Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(\u00ae)) in immunodeficiency diseases: real-life data from a monocentric experience","volume":"20","author":"Angelotti","year":"2020","journal-title":"Clin. Exp. Med"},{"key":"10.1016\/j.leukres.2023.107365_bib43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2217\/imt-2019-0175","article-title":"Ellerbroek PM. Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients","volume":"12","author":"Paassen","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.leukres.2023.107365_bib44","article-title":"Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation (Review)","volume":"4","author":"Raanani","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.leukres.2023.107365_bib45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/10245332.2018.1538001","article-title":"The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments","volume":"24","author":"Benbrahim","year":"2019","journal-title":"Hematology"},{"key":"10.1016\/j.leukres.2023.107365_bib46","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1111\/trf.14656","article-title":"Effectiveness of immunoglobulin prophylaxis in reducing clinical complications of hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"58","author":"Ahn","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.leukres.2023.107365_bib47","unstructured":"European Medicines Agency. Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg). Published 2018. Accessed July 17, 2023. \u3008https:\/\/www.ema.europa.eu\/en\/core-summary-product-characteristics-human-normal-immunoglobulin-intravenous-administration-ivig#document-history-section\u3009."},{"key":"10.1016\/j.leukres.2023.107365_bib48","unstructured":"European Medicines Agency. Hizentra Summary Of Product Characteristics. Published 2022. Accessed 17 July 2023. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hizentra-epar-product-information_en.pdf\u3009."},{"key":"10.1016\/j.leukres.2023.107365_bib49","unstructured":"European Medicines Agency. HyQvia, INN-human normal immunoblobulin (SCIg). Published 2020. Accessed 17 July 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hyqvia-epar-product-information_en.pdf."},{"key":"10.1016\/j.leukres.2023.107365_bib50","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI primary immunodeficiency and altered immune response committees","volume":"149","author":"Otani","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.leukres.2023.107365_bib51","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.tmrv.2007.01.001","article-title":"Guidelines on the use of intravenous immune globulin for hematologic conditions","volume":"21","author":"Anderson","year":"2007","journal-title":"Transfus. Med Rev."},{"key":"10.1016\/j.leukres.2023.107365_bib52","unstructured":"United Kingdom Department of Health. Updated commissioning criteria for the use of therapeutic immunoglobulin (Ig) in immunology, haematology, neurology and infectious diseases in England. Published 2019. Accessed July 17, 2023. https:\/\/igd.mdsas.com\/wp-content\/uploads\/NHSE_Commissioning_Criteria_for_the_use_of_Ig_V1.4_November_2019.pdf."},{"key":"10.1016\/j.leukres.2023.107365_bib53","unstructured":"United Kingdom Department of Health. Clinical guidelines for immunoglobulin use: Update to second edition. Published 2011. Accessed 17 July\u00a02023. https:\/\/www.gov.uk\/government\/publications\/clinical-guidelines-for-immunoglobulin-use-second-edition-update."},{"key":"10.1016\/j.leukres.2023.107365_bib54","unstructured":"Australian National Blood Authority. Qualifying criteria for Ig therapy - Acquired hypogammaglobulinaemia secondary to haematological malignancies, or post-haemopoietic stem cell transplantation (HSCT). Published 2020. Accessed July 17, 2023. https:\/\/www.criteria.blood.gov.au\/MedicalCondition\/View\/2621."},{"key":"10.1016\/j.leukres.2023.107365_bib55","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5152\/tpa.2014.2206","article-title":"Vaccination in patients with immunosuppression","volume":"49","author":"Arvas","year":"2014","journal-title":"Turk. Pediatr. Ars"},{"key":"10.1016\/j.leukres.2023.107365_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13223-014-0063-8","article-title":"Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapy","volume":"10","author":"Koterba","year":"2014","journal-title":"Allergy, Asthma Clin. Immunol."},{"key":"10.1016\/j.leukres.2023.107365_bib57","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/NAN.0000000000000087","article-title":"Subcutaneous immunoglobulin replacement therapy: ensuring success","volume":"38","author":"Younger","year":"2015","journal-title":"J. Infus. Nurs."},{"key":"10.1016\/j.leukres.2023.107365_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antib9020024","article-title":"Considerations for optimizing dosing of immunoglobulins based on pharmacokinetic evidence","volume":"9","author":"Mahmood","year":"2020","journal-title":"Antibodies"},{"key":"10.1016\/j.leukres.2023.107365_bib59","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/ajhp\/62.7.720","article-title":"Use of I.V. immune globulin and occurrence of associated acute renal failure and thrombosis","volume":"62","author":"Shah","year":"2005","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"10.1016\/j.leukres.2023.107365_bib60","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1592\/phco.2005.25.6.886","article-title":"Intravenous immunoglobulin-associated acute renal failure: case series and literature review","volume":"25","author":"Itkin","year":"2005","journal-title":"Pharmacotherapy"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:04:47Z","timestamp":1758935087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623006306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":60,"alternative-id":["S0145212623006306"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107365","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of humoral secondary immunodeficiency in hematological malignancies and following hematopoietic stem cell transplantation: Regional perspectives","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107365","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107365"}}